Login to Your Account

And Maybe More

Ovarian Trial 'MEKs' Big Year: Array Rolls Out Five Phase IIIs

By Randy Osborne
Staff Writer

Tuesday, May 7, 2013
Array BioPharma Inc.'s Phase III trial planned for this summer in recurrent low-grade serous ovarian cancer (LGSOC) with its Novartis AG-partnered MEK inhibitor is one of a handful of late-stage studies expected to roll out this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription